Abeona Therapeutics investor relations material

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. The company's initial focus is on amyotrophic lateral sclerosis therapy based on the conversion of skin cells into motor neurons. Furthermore, the company is developing TAHO, an attenuated adenovirus that is administered orally, for the treatment of patients who have severe combined immunodeficiency (SCID-X1), a rare genetic disease that causes immune system deficiency and increases susceptibility to infection in early childhood.